ARTICLE | Clinical News
H11 (NovoMAb-G2): Began Phase I/II trial
December 11, 2000 8:00 AM UTC
Viventia Biotech Inc. (TSE:VBI), Toronto, Ontario Product: H11 (NovoMAb-G2) Business: Cancer Therapeutic category: Antibody, Cytotoxic Target: Cancer cells Description: Recombinant pan-carcinoma speci...